BioPharma Dive February 8, 2024
Gwendolyn Wu

The fundraise is only the fourth initial stock offering of significant size for a preclinical biotech since October 2022, according to BioPharma Dive data.

Dive Brief:

  • Metagenomi, a gene editing startup spun out of research at the University of California, Berkeley, brought in about $93.8 million in the biotechnology sector’s sixth initial public offering of the year.
  • The company on Thursday sold 6.25 million shares at $15 apiece, toward the low end of a range it set earlier this week. The offering will fund the development of genetic medicines for a variety of conditions, including hemophilia and transthyretin amyloidosis.
  • The IPO makes Metagenomi one of the rare biotech companies to go public recently without a drug already in clinical...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Drugmakers counter HHS' first offers in Medicare price talks
Pfizer stops buildout of $350M Seagen plant, leaving 120 workers' roles in question
ARPA-H behind on duplicative research efforts, GAO says
Science Continues To Outpace Commercialization Of Cell And Gene Therapies
Opinion: Missing data is making it difficult for the pharmaceutical industry to help LGBTQ+ people

Share This Article